HK1131210A1 - Improved immunoassay methods - Google Patents

Improved immunoassay methods

Info

Publication number
HK1131210A1
HK1131210A1 HK09110819.9A HK09110819A HK1131210A1 HK 1131210 A1 HK1131210 A1 HK 1131210A1 HK 09110819 A HK09110819 A HK 09110819A HK 1131210 A1 HK1131210 A1 HK 1131210A1
Authority
HK
Hong Kong
Prior art keywords
immunoassay methods
improved immunoassay
improved
methods
immunoassay
Prior art date
Application number
HK09110819.9A
Other languages
English (en)
Inventor
John Forsyth Russell Robertson
Andrea Murray
Caroline Chapman
Tony Barnes
Original Assignee
Oncimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0618055A external-priority patent/GB2441824A/en
Application filed by Oncimmune Ltd filed Critical Oncimmune Ltd
Publication of HK1131210A1 publication Critical patent/HK1131210A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
HK09110819.9A 2006-09-13 2009-11-19 Improved immunoassay methods HK1131210A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84415806P 2006-09-13 2006-09-13
GB0618055A GB2441824A (en) 2006-09-13 2006-09-13 Immunoassay method
PCT/GB2007/003486 WO2008032084A1 (en) 2006-09-13 2007-09-12 Improved immunoassay methods

Publications (1)

Publication Number Publication Date
HK1131210A1 true HK1131210A1 (en) 2010-01-15

Family

ID=38626957

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09110819.9A HK1131210A1 (en) 2006-09-13 2009-11-19 Improved immunoassay methods

Country Status (8)

Country Link
EP (1) EP2062053B1 (ja)
JP (3) JP5495159B2 (ja)
AU (1) AU2007297310B2 (ja)
CA (1) CA2663154C (ja)
HK (1) HK1131210A1 (ja)
IL (1) IL197487A (ja)
PL (1) PL2062053T3 (ja)
WO (1) WO2008032084A1 (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810040D0 (en) 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
GB2424273B (en) 2002-11-14 2007-06-27 Univ Nottingham Method for preparing tumour marker protein
RU2636532C2 (ru) 2005-05-27 2017-11-23 Онкиммьюн Лимитед Улучшенные способы иммуноанализа
GB2426581A (en) 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
CN101632020B (zh) 2006-09-13 2013-11-27 昂西免疫有限公司 改进的免疫测定方法
GB0725239D0 (en) * 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay
KR20120098992A (ko) * 2009-06-23 2012-09-06 이벤투스 디아그노스틱스 이스라엘 리미티드 암의 검출을 위한 방법 및 시스템
JP5257788B2 (ja) * 2009-12-02 2013-08-07 日東紡績株式会社 クラスリン重鎖とその自己抗体との複合体の免疫測定方法、それに用いるキット及びそれを用いた癌判定方法
RU2600891C2 (ru) * 2010-08-26 2016-10-27 Юниверсити Оф Вашингтон Тру Итс Сентер Фор Коммерсиализейшен Способы выявления антител против не4 и способы диагностики и/или прогнозирования состояний, ассоциированных с экспрессирующими не4 клетками
DE102010047069A1 (de) * 2010-10-01 2012-04-05 Universitätsklinikum Kiel Schleswig-Holstein Differenzialdiagnostik von Pankreasadenomen
JP6074677B2 (ja) * 2012-08-07 2017-02-08 学校法人北里研究所 膀胱癌診断用ポリペプチドマーカー及び膀胱癌診断用キット並びにこれらを使用する方法
JP6371063B2 (ja) * 2013-01-30 2018-08-08 国立大学法人 岡山大学 悪性腫瘍の検査方法および抗腫瘍剤
US20160291025A1 (en) * 2013-09-18 2016-10-06 Adelaide Research & Innovation Pty Ltd Autoantibody biomarkers of ovarian cancer
EP3102944B1 (en) 2014-02-04 2018-10-10 CellTrend GmbH Diagnosis of cancer by detecting auto-antibodies against egf-receptor
GB201403489D0 (en) * 2014-02-27 2014-04-16 Univ London Queen Mary Biomarkers for endometriosis
JP6739345B2 (ja) * 2014-03-18 2020-08-12 サンフォード ヘルス 乳癌検出のための試薬および方法
ES2876038T3 (es) 2018-02-18 2021-11-11 Marquez Marquez Lidia Método, aparato y kit para la detección temprana de cáncer de mama
WO2020097901A1 (en) * 2018-11-16 2020-05-22 Beijing Percans Oncology Co. Ltd. Biomarkers for cancer therapy
WO2020034061A1 (en) * 2018-08-13 2020-02-20 Beijing Percans Oncology Co., Ltd. Biomarkers for cancer therapy
WO2024057956A1 (ja) * 2022-09-12 2024-03-21 チューニングフォーク・バイオ・インク ｐ５３アイソフォーム変異体のがん診断用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60196669A (ja) * 1984-03-21 1985-10-05 Hitachi Ltd 抗原抗体反応用分析方法および装置
JP3005400B2 (ja) * 1993-09-16 2000-01-31 株式会社トクヤマ 抗原または抗体濃度の測定方法
JP3476274B2 (ja) * 1995-04-24 2003-12-10 積水化学工業株式会社 免疫測定法
JPH10239317A (ja) * 1996-12-28 1998-09-11 Shinotesuto:Kk 地帯現象抑制測定方法及び測定試薬
GB9810040D0 (en) * 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
US20010026920A1 (en) * 2000-02-25 2001-10-04 Mark Chandler Internal standards and controls for multiplexed assay
GB2424273B (en) * 2002-11-14 2007-06-27 Univ Nottingham Method for preparing tumour marker protein
JP2005049264A (ja) * 2003-07-30 2005-02-24 Fujikura Kasei Co Ltd 標的物質の測定方法および測定試薬
GB2426581A (en) * 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods

Also Published As

Publication number Publication date
AU2007297310A1 (en) 2008-03-20
EP2062053A1 (en) 2009-05-27
JP5495159B2 (ja) 2014-05-21
JP2014016364A (ja) 2014-01-30
CA2663154C (en) 2016-02-23
JP2012255797A (ja) 2012-12-27
JP2010503845A (ja) 2010-02-04
JP5736598B2 (ja) 2015-06-17
PL2062053T3 (pl) 2013-05-31
IL197487A0 (en) 2009-12-24
IL197487A (en) 2013-08-29
CA2663154A1 (en) 2008-03-20
EP2062053B1 (en) 2012-12-05
AU2007297310B2 (en) 2013-11-07
WO2008032084A1 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
HK1131210A1 (en) Improved immunoassay methods
GB0615662D0 (en) Antibody
IL194892A0 (en) Nonseparation assay methods
PL2021778T3 (pl) Nieseparacyjne metody oznaczania
PT2011869E (pt) Novo anticorpo anti-cd98
IL196268A0 (en) Assay methods
GB0613209D0 (en) Methods
GB0600967D0 (en) Methods
EP2015785A4 (en) ANTIGEN AGRM2
GB0608941D0 (en) Methods
IL215528A0 (en) Improved immunoassay methods
PT2062053E (pt) Métodos de imunoensaio melhorados
EP2115136A4 (en) NOVEL PROCEDURE
GB0607377D0 (en) Novel Methods
GB0621095D0 (en) Assay method
GB0607376D0 (en) Antibodies
GB0606276D0 (en) Antibodies
ZA200709879B (en) Improved immunoassay methods
GB0606198D0 (en) Methods
GB0618704D0 (en) Methods
GB0625194D0 (en) Methods
GB0611208D0 (en) Methods
GB0625193D0 (en) Methods
GB0618836D0 (en) Methods
GB0624391D0 (en) Methods

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180917